• Equity advice to Investors on a buy, hold, and sell type rating on specific core technologies in biopharmaceuticals:  Core business model, company fundamentals, and valuation.

• Valuation and technology assessment services to underwriters for appropriate pricing of biotech IPOs.

• Biotech newsletter that contains alerts for fundamental changes and valuation impacts in our core technology portfolio and the dominant companies in that space -- complimentary to registered users of BioValues.

• Facilitate funding for new Biotech startups based on rigorous scientific and financial criteria.

• Facilitate due diligence on and valuation of technology transfers.

Please contact us with questions, comments or enquiries about our portfolio of services.  Click here to register to receive our informative monthly biotech letter.